Increasing transparency in partnerships for health - introducing the Green Light Committee
Increasing transparency in partnerships for health - introducing the Green Light Committee
复制标题
DOI：
10.1046/j.1365-3156.2002.00960.x
复制
发表时间：
2002-11-01
影响因子：
3.3
通讯作者：
Varaine, F
中科院分区：
文献类型：
--
作者：
Gupta, R;Cegielski, JP;Varaine, F
公私伙伴关系已成为防治传染病努力的核心。随着经验的积累，具体伙伴关系的特点、管理结构及其有效解决问题的能力正在得到澄清。为了促进获得和合理使用二线抗结核药物来治疗耐多药结核病，世界卫生组织建立了一个独特的伙伴关系，称为绿色光委员会。这一伙伴关系依靠五类行为者来实现其目标：学术机构、民间社会组织、双边捐助者、资源有限国家的政府和联合国专门机构。虽然营利性私营部门参与提供优惠价格的药物，但它被排除在决策之外。伙伴关系的有效性体现在其审查过程、修改工作方式以克服障碍的灵活性、独立于商业部门以及将获取、合理使用、技术援助和政策制定联系起来的能力。全球传染病控制机制可能有助于发展其他伙伴关系，以便合理分配资源和工具，防治其他传染病。
Public-private partnerships have become central to efforts to combat infectious diseases. The characteristics of specific partnerships, their governance structures, and their ability to effectively address the issues for which they are developed are being clarified as experience is gained. In an attempt to promote access to and rational use of second-line anti-tuberculosis (TB) drugs for the treatment of multidrug-resistant TB, a unique partnership known as the Green Light Committee (GLC) was established by the World Health Organization. This partnership relies on five categories of actors to achieve its goal: academic institutions, civil society organizations, bilateral donors, governments of resource-limited countries, and a specialized United Nations agency. While the for-profit private sector is involved in terms of supplying concessionally priced drugs it is excluded from decision-making. The effectiveness of the partnership emerges from its review process, flexibility to modify its modus operandi to overcome obstacles, independence from the commercial sector, and its ability to link access, rational use, technical assistance, and policy development. The GLC mechanism may be useful in the development of other partnerships needed in the rational allocation of resources and tools for combating additional infectious diseases.